Antimicrobial resistance | Socioclinic characteristics | |
---|---|---|
AOR (95% CI) | P-value | |
 | Male | |
 Ampicillin | 2.69 (1.37–5.3) |  < 0.01 |
 Ciprofloxacin | 4.18 (1.94–9.01) |  < 0.001 |
 Cefotaxime | 1.77 (1.008–3.12) | 0.04 |
 Benzylpenicillin | 0.17 (0.03–0.85) | 0.03 |
 Amikacin | 4.9 (1.04–23.3) | 0.04 |
 | Neonates and infants | |
 Cefalotin | 0.04 (0.007–0.27) |  < 0.01 |
 Cefotaxime | 0.60 (0.009–0.38) |  < 0.01 |
 Benzylpenicillin | 21.29 (1.99–227.51) | 0.01 |
 | Early childhood | |
 Cefalotin | 0.11 (0.015–0.871) | 0.03 |
 | Late childhood | |
 Cefalotin | 0.04 (0.005–0.43) |  < 0.01 |
 Cefotaxime | 0.08 (0.009–0.82) | 0.03 |
 | Urinary burning |  |
 Ciprofloxacin | 0.30 (0.09–0.98) | 0.04 |
 | Abdominal pelvic pain | |
 Trimethoprim-sulfamethoxazole | 6.75 (1.11–41.03) | 0.03 |
 | Pollakiuria | |
 Ciprofloxacin | 0.21 (0.06–0.73) | 0.01 |
 | Treatment failure | |
 Amoxicillin-clavulanic acid | 1.83 (1.03–3.26) | 0.03 |
 Cefalotin | 2.08 (1.64–3.74) | 0.01 |
 Gentamicin | 1.95 (1.05–3.61) | 0.03 |
 Ampicillin | 0.048 (0.004–0.61) | 0.02 |
 | Recurrent UTIs | |
 Trimethoprim-sulfamethoxazole | 18.75 (1.26–278.67) | 0.03 |